Shumei Kato

University of California, San Diego
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

The serine/threonine kinase BRAF is frequently mutated in several tumor types, including melanoma and non-small cell lung cancer (NSCLC). Oncogenic BRAF mutations can be classified as Class I, II, or III owing to differences in underlying oncogenic mechanisms. While there are approved targeted therapies for BRAF Class I mutants, there are no approved targeted therapy strategies for Class II and Class III BRAF mutated cancers. By leveraging analysis of a large, real world circulating tumor DNA (ctDNA) profiling database, we highlight a significant subset of NSCLC patients whose tumors harbored Class II and Class III BRAF mutations. These mutations comprise ~65% of BRAF-mutant NSCLC cases, with Class II patients showing significantly worse clinical outcomes compared to Class I patients. In several preclinical tumor systems with Class II and III BRAF mutations, exarafenib, a novel type 2 pan-RAF inhibitor that binds RAF proteins irrespective of isoform or dimerization state, demonstrates robust anti-tumor activity. Initial clinical evaluation also showed promising activity in Class II BRAF-mutant NSCLC patients. Mechanistic studies reveal that exarafenib resistance involves adaptive rewiring from conventional oncogenic BRAF-dependent signaling to an ARAF-mediated bypass pathway, characterized by drug-induced ARAF-KSR1 scaffolding complexes that maintain MAPK signaling despite pan-RAF inhibitor treatment. This resistance is driven by upstream RTK activation and RAS-GTP accumulation, which specifically promotes complex assembly under drug treatment. Based on these insights, we identified MEK inhibition as a rational combination strategy that overcomes resistance by targeting the convergence point of both signaling pathways. The exarafenib plus binimetinib combination demonstrated superior efficacy in diverse preclinical models. This study establishes ARAF-KSR1 complex formation as a novel resistance mechanism to pan-RAF inhibition and provides mechanistic rationale for combination strategies with potential to address the unmet clinical need for BRAF Class II and III-mutated NSCLC.

Year:

2025

Purpose: Despite efficacy of approved FGFR inhibitors, emergence of polyclonal secondary mutations in the FGFR kinase domain leads to acquired resistance. KIN-3248 is a selective, irreversible, orally bioavailable, small-molecule inhibitor of FGFR1-4 that blocks both primary oncogenic and secondary kinase domain resistance FGFR alterations. Experimental Design: A first-in-human, phase I study of KIN-3248 was conducted in patients with advanced solid tumors harboring FGFR2 and/or FGFR3 gene alterations (NCT05242822). The primary objective was determination of MTD/recommended phase II dose (RP2D). Secondary and exploratory objectives included antitumor activity, pharmacokinetics, pharmacodynamics, and molecular response by circulating tumor DNA (ctDNA) clearance. Results: Fifty-four patients received doses ranging from 5 to 50 mg orally daily across six cohorts. Intrahepatic cholangiocarcinoma (48.1%), gastric (9.3%), and urothelial (7.4%) were the most common tumors. Tumors harbored FGFR2 (68.5%) or FGFR3 (31.5%) alterations—23 (42.6%) received prior FGFR inhibitors. One dose-limiting toxicity (hypersensitivity) occurred in cohort 1 (5 mg). Treatment-related, adverse events included hyperphosphatemia, diarrhea, and stomatitis. The MTD/RP2D was not established. Exposure was dose proportional and concordant with hyperphosphatemia. Five partial responses were observed; 4 in FGFR inhibitor naïve and 1 in FGFR pretreated patients. Pretreatment ctDNA profiling confirmed FGFR2/3 alterations in 63.3% of cases and clearance at cycle 2 associated with radiographic response. Conclusion: The trial was terminated early for commercial considerations; therefore, RP2D was not established. Preliminary clinical data suggest that KIN-3248 is a safe, oral FGFR1-4 inhibitor with favorable pharmacokinetic parameters, though further dose escalation was required to nominate the MTD/RP2D. Significance: KIN-3248 was a rationally designed, next generation selective FGFR inhibitor, that was effective in interfering with both FGFR wild-type and mutant signaling. Clinical data indicate that KIN-3248 is safe with a signal of antitumor activity. Translational science support the mechanism of action in that serum phosphate was proportional with exposure, paired biopsies suggested phospho-ERK inhibition (a downstream target of FGFR2/3), and ctDNA clearance may act as a RECIST response surrogate.

Year:

2024

Antitumor activity. A, Best percent change in target lesions by KIN-3248 starting dose level. Bars are color-coded by the gene (FGFR2 or FGFR3) that was altered according to the molecular report provided for study eligibility evaluation (local testing). Bars are labeled with the best overall response for each evaluable participant. X -axis is labeled with the tumor type of each participant, with the labels color-coded (black or red) to show which participants have been previously treated (*) with one or more FGFR inhibitors. Participants with documented on-target acquired resistance mutations, either by local testing or central ctDNA analysis, are indicated with distinct symbols. B, Twenty-six patients were evaluable for efficacy and were tested by central ctDNA analysis. Box and whisker plot of change in mean variant allele frequency of ctDNA after first cycle of KIN-3248 treatment by best overall response. C, Scatter plot of change in mean variant allele frequency of ctDNA after first cycle of KIN-3248 treatment by best % change in target lesions. X-axis direction is reversed. Linear fit with SE. Pearson R = 0.45, P = 0.021.

Year:

2024

Serum phosphate by KIN-3248 C1D1 exposure. Baseline and on-treatment serum phosphate were measured locally in all 54 participants. A, Scatter plot of serum phosphate (mg/dL) after approximately 1 week on KIN-3248 by KIN-3248 C1D1 exposure (AUC0–24). Significant correlation between KIN-3248 exposure and serum phosphate level after approximately 1 week of treatment (nominal C1D8: actual study days 6, 7, 8 or 9). Linear fit with SE. Pearson R = 0.55, P = 1.7e-5. B, Scatter plot of initial change in serum phosphate by KIN-3248 C1D1 exposure (AUC0–24). Significant correlation between C1D1 KIN-3248 exposure and the initial change (∼1 week) in serum phosphate (PhosC1D8 – PhosC1D1). Pearson R = 0.62, P = 7.1e-7. One participant was missing the C1D1 phosphate measurement, so the screening measurement was used as the baseline value for that participant.

Year:

2024

Serum phosphate by KIN-3248 C1D1 exposure. Baseline and on-treatment serum phosphate were measured locally in all 54 participants. A, Scatter plot of serum phosphate (mg/dL) after approximately 1 week on KIN-3248 by KIN-3248 C1D1 exposure (AUC0–24). Significant correlation between KIN-3248 exposure and serum phosphate level after approximately 1 week of treatment (nominal C1D8: actual study days 6, 7, 8 or 9). Linear fit with SE. Pearson R = 0.55, P = 1.7e-5. B, Scatter plot of initial change in serum phosphate by KIN-3248 C1D1 exposure (AUC0–24). Significant correlation between C1D1 KIN-3248 exposure and the initial change (∼1 week) in serum phosphate (PhosC1D8 – PhosC1D1). Pearson R = 0.62, P = 7.1e-7. One participant was missing the C1D1 phosphate measurement, so the screening measurement was used as the baseline value for that participant.

Year:

2024

Purpose: Despite efficacy of approved FGFR inhibitors, emergence of polyclonal secondary mutations in the FGFR kinase domain leads to acquired resistance. KIN-3248 is a selective, irreversible, orally bioavailable, small-molecule inhibitor of FGFR1-4 that blocks both primary oncogenic and secondary kinase domain resistance FGFR alterations. Experimental Design: A first-in-human, phase I study of KIN-3248 was conducted in patients with advanced solid tumors harboring FGFR2 and/or FGFR3 gene alterations (NCT05242822). The primary objective was determination of MTD/recommended phase II dose (RP2D). Secondary and exploratory objectives included antitumor activity, pharmacokinetics, pharmacodynamics, and molecular response by circulating tumor DNA (ctDNA) clearance. Results: Fifty-four patients received doses ranging from 5 to 50 mg orally daily across six cohorts. Intrahepatic cholangiocarcinoma (48.1%), gastric (9.3%), and urothelial (7.4%) were the most common tumors. Tumors harbored FGFR2 (68.5%) or FGFR3 (31.5%) alterations—23 (42.6%) received prior FGFR inhibitors. One dose-limiting toxicity (hypersensitivity) occurred in cohort 1 (5 mg). Treatment-related, adverse events included hyperphosphatemia, diarrhea, and stomatitis. The MTD/RP2D was not established. Exposure was dose proportional and concordant with hyperphosphatemia. Five partial responses were observed; 4 in FGFR inhibitor naïve and 1 in FGFR pretreated patients. Pretreatment ctDNA profiling confirmed FGFR2/3 alterations in 63.3% of cases and clearance at cycle 2 associated with radiographic response. Conclusion: The trial was terminated early for commercial considerations; therefore, RP2D was not established. Preliminary clinical data suggest that KIN-3248 is a safe, oral FGFR1-4 inhibitor with favorable pharmacokinetic parameters, though further dose escalation was required to nominate the MTD/RP2D. Significance: KIN-3248 was a rationally designed, next generation selective FGFR inhibitor, that was effective in interfering with both FGFR wild-type and mutant signaling. Clinical data indicate that KIN-3248 is safe with a signal of antitumor activity. Translational science support the mechanism of action in that serum phosphate was proportional with exposure, paired biopsies suggested phospho-ERK inhibition (a downstream target of FGFR2/3), and ctDNA clearance may act as a RECIST response surrogate.

Year:

2024

Antitumor activity. A, Best percent change in target lesions by KIN-3248 starting dose level. Bars are color-coded by the gene (FGFR2 or FGFR3) that was altered according to the molecular report provided for study eligibility evaluation (local testing). Bars are labeled with the best overall response for each evaluable participant. X -axis is labeled with the tumor type of each participant, with the labels color-coded (black or red) to show which participants have been previously treated (*) with one or more FGFR inhibitors. Participants with documented on-target acquired resistance mutations, either by local testing or central ctDNA analysis, are indicated with distinct symbols. B, Twenty-six patients were evaluable for efficacy and were tested by central ctDNA analysis. Box and whisker plot of change in mean variant allele frequency of ctDNA after first cycle of KIN-3248 treatment by best overall response. C, Scatter plot of change in mean variant allele frequency of ctDNA after first cycle of KIN-3248 treatment by best % change in target lesions. X-axis direction is reversed. Linear fit with SE. Pearson R = 0.45, P = 0.021.

Year:

2024

PURPOSE Human epidermal growth factor receptor 2 (HER2) expression (protein immunohistochemistry [IHC] or gene amplification [copy-number variation, CNV]) predicts anti-HER2 therapy responsiveness, although recently it was shown that even low HER2-expressing breast cancers benefit from trastuzumab-deruxtecan. Little is known about HER2 transcriptomic (mRNA) expression, and comparisons between genomic, mRNA, and protein HER2 assays. METHODS HER2 status was evaluated using clinical-grade IHC (protein), quantitative reverse transcription polymerase chain reaction (mRNA), and next-generation sequencing (NGS; amplifications). RESULTS Multi-institutional HER2 testing was performed on 5,305 diverse cancers including non–small-cell lung (n = 1,175), breast (n = 1,040), and colon cancers (n = 566; N = 3,926 tested for CNV; N = 1,848, mRNA; N = 2,533, IHC). Overall, 4.1% (161/3,926) had NGS HER2 amplification; 33.3% (615/1,848) had mRNA overexpression; and 9.3% (236/2,533) were IHC-positive. In 723 patients with all three tests (CNV/mRNA/IHC), various amplification/expression patterns occurred: 7.5% (54/723) had all three HER2 tests positive; 62.8% (454/723) had all three tests negative. Discrepant patterns between amplification and overexpression emerged. For instance, 20% (144/723) of patients had mRNA overexpression alone with negative CNV and IHC. A range in values for only mRNA+ cases occurred in different tumor types (eg, 16.9%, breast; 5%, hepatobiliary). There were 53 patients with various tumors from our institution who had all three assays attempted; 22 tested positive for HER2, and seven received anti-HER2 therapy: two patients achieved response: one (esophageal cancer), complete response (≥42 months); one (cholangiocarcinoma), who only had HER2 mRNA positivity (tissue was inadequate for IHC and CNV assessment), partial response (≥24 months) on HER2-based regimens. CONCLUSION We demonstrate variability of HER2 (protein and mRNA) expression and amplification using comprehensive assays (CNV, mRNA, and IHC) among diverse cancers. As HER2-targeted therapy indications expand, the relative importance of these modalities merits further evaluation.

Year:

2023

Collaborators (5)

James Harding

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Mitesh Borad

Professor of Medicine

Mayo Clinic

UNITED STATES
View details

WEI WU

University of California, San Francisco

UNITED STATES
View details

Trever Bivona

Professor

University of California, San Francisco

UNITED STATES
View details

Do-Youn Oh

Professor

Seoul National University Hospital

SOUTH KOREA
View details